Australian Pharmaceutical Industries closes 2018 with pharmacy deal
Australian Pharmaceutical Industries (ASX: API) closed out 2018 by announcing it acquired Sigma Healthcare Ltd (ASX: SIG), a wholesale and distribution service for pharmacies. With $2.96 million of reported revenue in FY2018, Sigma also owns several pharmacy retail brands in Australia such as Amcal Max, DDS, Amcal, and Guardian. The deal was valued at $524.9 million (AUD $727 million), which is a 46.5% premium to Sigma’s one-month volume weighted average share price of $0.34 at the close of trading on December 13. Australian Pharmaceutical Industries (API) offers wholesale product delivery, retail services, marketing programs, and business advisory services. Not only will API gain... Read More »
Biotechnology and Digital Health Deals Lead for December
Although December is typically one of the slower months in transaction announcements, the eHealth and Biotechnology sectors remained the most active with a total of 27 transactions, growing in proportion compared to December 2017. Biotechnology and e-Health transactions were roughly 19% of all of December 2017’s deals, but they were 28% this December. However, price volume tells a different story. Compared to December 2017, the total of disclosed prices saw an 84% decrease in the Biotechnology sector, going from $2.66 billion to only $425 million. In the e-Health sector, however, there was a 1,285% increase in purchase amount, going from $88.8 million in December 2017 to $1.23... Read More »
Propeller Health Flies to ResMed
And Propeller Health makes three. Three deals in 2018, that is, for ResMed Inc. (NYSE: RMD), which picked up Propeller for $225 million on December 3. ResMed is a global medical device maker with more than 6 million cloud-connected devices for daily remote patient monitoring for conditions like sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Propeller Health is a digital therapeutics company based in Madison, Wisconsin and backed by Aptar Pharma, Safeguard Scientifics, Social Capital, Hikma, 3M Ventures and SR One. Its products treat COPD patients in Stage 2 and 3 severity levels through connectivity, analytics and companion digital experiences.... Read More »
UPMC’s Curavi Health Acquires TripleCare Telemedicine
Curavi Health, Inc., a portfolio company of UPMC Enterprises, has acquired TripleCare, a telemedicine company in the post-acute and long-term care sectors, mirroring a growing trend in the e-health sector of the healthcare industry. Curavi’s takeover of TripleCare will give Curavi command of nearly 100 facilities across 14 states in the United States. TripleCare’s telemedicine platform offers post-acute care patients the opportunity to get treatment from physicians at home, without having to endure costly visits to the emergency room or hospitalizations. Financial terms of the acquisition were not disclosed. This deal echoes InTouch Health’s April 2018 purchase of REACH Health, whose REACH... Read More »
